Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Novo Nordisk's diabetes drug

Novo Nordisk has received approval from the US FDA for its type 2 diabetes treatment, Victoza (liraglutide)

Danish pharmaceutical company, Novo Nordisk has announced it has been granted marketing authorisation from the US Food and Drug Administration (FDA) for its type 2 diabetes treatment, Victoza (liraglutide).

Victoza is approved for use in addition to diet and exercise to improve glycaemic control in adults with type 2 diabetes. It is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of type 2 diabetes.

"The US approval of Victoza represents a major advancement in the treatment of type 2 diabetes and is an important milestone for Novo Nordisk that follows the recent approval in Japan and the ongoing successful launch in Europe." said Lars Rebien Sørensen, president and CEO.

He continued: "We are convinced that Victoza will prove to be a valuable treatment option for people with type 2 diabetes in the US. The ability of Victoza to substantially improve glucose control with a low risk of hypoglycaemia creates an opportunity for more patients with type 2 diabetes to achieve their individual treatment goals."

Novo Nordisk plans to introduce Victoza to the US market within the next few weeks.

26th January 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics